Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

• Status: Recruiting
• Trial end date: 2022-06-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Desvenlafaxine Succinate; Vortioxetine

Criteria

Inclusion Criteria:

• The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).

• The patient has a MADRS total score ≥24 at screening and baseline.

• The patient has had the current MDE for ≥3 months and < 12 months.

• The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.

• The patient wants to switch antidepressant treatment.

Exclusion Criteria:

• The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.

Other in- and exclusion criteria may apply